- Conditions
- Respiratory Syncytial Viruses
- Interventions
- ABRYSVO Vaccination
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Months to 6 Months
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 143
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 841 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 8
- States / cities
- Coral Gables, Florida • Savannah, Georgia • Evansville, Indiana + 5 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, HZ/su VACCINE
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 526 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 22 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine (GSK3844766A)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Lenexa, Kansas • Elkridge, Maryland • Omaha, Nebraska + 4 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Not listed
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 293,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- RSV vaccine formulation 1, RSV vaccine formulation 2, Placebo
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 18 Months
- Enrollment
- 259 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 25
- States / cities
- Gardena, California • La Mesa, California • Los Angeles, California + 21 more
- Conditions
- Lymphoma
- Interventions
- AREXVY, ABRYSVO, PREVNAR 20, PNEUMOVAX 23, Heplisav -B, PREVNAR 13, Shingrix
- Drug · Biological
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2036
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy
- Interventions
- IVX-A12, Placebo
- Biological
- Lead sponsor
- Icosavax, Inc.
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 10
- States / cities
- Tempe, Arizona • Hollywood, Florida • Stockbridge, Georgia + 7 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Moderna RSV vaccine
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Saline Placebo (0.5mL injection), RSV F vaccine (0.5mL injection)
- Drug
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 7
- States / cities
- Nampa, Idaho • Hutchinson, Kansas • Kansas City, Kansas + 4 more
- Conditions
- Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
- Interventions
- RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1
- Biological · Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 2,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 50
- States / cities
- Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV LID ΔM2-2 Vaccine, Placebo Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 7
- States / cities
- Alhambra, California • La Jolla, California • Aurora, Colorado + 3 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Placebo, mRNA-1345
- Drug
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 36,814 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 133
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 114 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 349 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, PCV20
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,113 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Guntersville, Alabama • Phoenix, Arizona • Huntington Beach, California + 17 more
- Conditions
- Respiratory Syncytial Virus Infection, Healthy Volunteers, Metapneumovirus Infection
- Interventions
- RSV/hMPV mRNA LNP 1, RSV/hMPV mRNA LNP 2, RSV mRNA LNP 1, hMPV mRNA LNP 1
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 558 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 9
- States / cities
- Gardena, California • Hallandale, Florida • Meridian, Idaho + 6 more
- Conditions
- RSV Infection
- Interventions
- Nirsevimab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- Up to 12 Months
- Enrollment
- 3,750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Covid19
- Interventions
- Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray
- Biological
- Lead sponsor
- Meissa Vaccines, Inc.
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Raleigh, North Carolina
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV MAT 60 µg, RSV MAT 120 µg, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 534 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Huntington Park, California • Los Angeles, California + 10 more
- Conditions
- Respiratory Syncytial Virus Infection Prevention
- Interventions
- Ad26.RSV.preF-based Vaccine, Placebo
- Biological · Other
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,124 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Coral Gables, Florida • Miami, Florida • El Dorado, Kansas + 4 more
- Conditions
- Healthy
- Interventions
- MEDI-534, Cohort 1, Placebo, Cohort 1, MEDI-534, Cohort 2, Placebo, Cohort 2, MEDI-534, Cohort 3, Placebo, Cohort 3, MEDI-534, Cohort 4, Placebo, Cohort 4, MEDI-534, Cohort 5, Placebo, Cohort 5
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 2 Months to 23 Months
- Enrollment
- 1,338 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 51
- States / cities
- Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 44 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- VXA-RSV-f Tablets (high dose), VXA Placebo Tablets, VXA-RSV-f Tablets (low dose)
- Biological · Other
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Melbourne, Florida
- Conditions
- Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
- Interventions
- FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Durham, North Carolina
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Adjuvanted RSVPreF3 vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Lexington, Kentucky • St Louis, Missouri • Omaha, Nebraska + 3 more